omeprazole has been researched along with Liver Diseases in 11 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the reliability of the omeprazole hydroxylation index as a marker for polymorphic CYP2C19 activity in a Japanese population of healthy young subjects (n = 78) and patients with peptic ulcer (n = 72)." | 5.09 | Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. ( Higuchi, S; Ieiri, I; Iimori, E; Kimura, M; Mamiya, K; Otsubo, K; Sakai, T; Urae, A; Wada, Y, 1999) |
| "To examine the pharmacokinetics of omeprazole during intravenous infusion in patients with varying degrees of liver dysfunction (Child-Pugh categories A to C)." | 3.71 | Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. ( de Prada, G; Feu, F; Hasselgren, G; Piqué, JM; Röhss, K, 2002) |
| "Omeprazole was given (40 mg/day) for 2 or 4 weeks." | 2.70 | Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease. ( Abdel-Baset, EZ; Atta, MM; Kabil, SM; Murray, JA; Nassar, AK; Shahin, WA, 2001) |
| " If two drugs of the same class have a similar dose-efficacy profile, then the favourable/unfavourable balance of the pharmacokinetic characteristics of the drugs may determine the drug of choice." | 2.39 | Pharmacokinetics--a relevant factor for the choice of a drug? ( Benet, LZ; Zech, K, 1994) |
| "Pantoprazole was well tolerated." | 1.31 | Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. ( Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001) |
| " The omeprazole metabolic ratio may serve the double purpose of phenotyping for CYP2C19 and to individualize dosing in omeprazole-treated patients." | 1.29 | Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. ( Brockmöller, J; Esdorn, F; Roots, I; Rost, KL, 1995) |
| " Following 10 mg intravenous omeprazole, plasma clearance was reduced, and plasma half-life and area under the concentration curve were increased, in comparison with previous studies in healthy subjects." | 1.27 | The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease. ( Carter, DC; Forrest, JA; Garden, OJ; MacGilchrist, AJ; McKee, RF, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ono, K | 1 |
| Takeda, M | 1 |
| Makihata, E | 1 |
| Okazaki, J | 1 |
| Nagai, A | 1 |
| Owens, SL | 1 |
| Parnell, NK | 1 |
| Piqué, JM | 1 |
| Feu, F | 1 |
| de Prada, G | 1 |
| Röhss, K | 1 |
| Hasselgren, G | 1 |
| Solomon, LK | 1 |
| Vogiatzis, I | 1 |
| Craig, E | 1 |
| Campbell, FC | 1 |
| Benet, LZ | 1 |
| Zech, K | 1 |
| Rost, KL | 1 |
| Brockmöller, J | 1 |
| Esdorn, F | 1 |
| Roots, I | 1 |
| Kimura, M | 1 |
| Ieiri, I | 1 |
| Wada, Y | 1 |
| Mamiya, K | 1 |
| Urae, A | 1 |
| Iimori, E | 1 |
| Sakai, T | 1 |
| Otsubo, K | 1 |
| Higuchi, S | 1 |
| Shahin, WA | 1 |
| Abdel-Baset, EZ | 1 |
| Nassar, AK | 1 |
| Atta, MM | 1 |
| Kabil, SM | 1 |
| Murray, JA | 1 |
| Ferron, GM | 1 |
| Preston, RA | 1 |
| Noveck, RJ | 1 |
| Pockros, P | 1 |
| Mayer, P | 1 |
| Getsy, J | 1 |
| Turner, M | 1 |
| Abell, M | 1 |
| Paul, J | 1 |
| Camara, DS | 1 |
| Corasanti, JG | 1 |
| McKee, RF | 1 |
| MacGilchrist, AJ | 1 |
| Garden, OJ | 1 |
| Forrest, JA | 1 |
| Carter, DC | 1 |
2 reviews available for omeprazole and Liver Diseases
| Article | Year |
|---|---|
Pharmacokinetics--a relevant factor for the choice of a drug?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aging; Benzimidazoles; Biological Ava | 1994 |
Update: gastroenterology and hepatology.
Topics: Chronic Disease; Esophageal Diseases; Gastrointestinal Diseases; Humans; Interferons; Liver Diseases | 1991 |
2 trials available for omeprazole and Liver Diseases
| Article | Year |
|---|---|
Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Topics: Adult; Age Factors; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 1999 |
Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease.
Topics: Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Female; Helicobacter Infections; Helicoba | 2001 |
7 other studies available for omeprazole and Liver Diseases
| Article | Year |
|---|---|
Perforation of a duodenal ulcer into a non-parasitic liver cyst: a rare case of a penetrate hole blockaded with conservative medical management.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cefoperazone; Cysts; Drug Therapy, Combination; Duodenal U | 2014 |
What is the evidence? Portosystemic shunt in a dog.
Topics: Animals; Anti-Ulcer Agents; Diet; Dog Diseases; Dogs; Evidence-Based Medicine; Gastrointestinal Hemo | 2011 |
Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.
Topics: Adult; Aged; Area Under Curve; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up | 2002 |
Hepatic penetration of a single large duodenal ulcer.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal Ulcer; Fatal Outcome; Humans; Liver Diseases; M | 2005 |
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Ulcer A | 1995 |
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Dose-Response Rela | 2001 |
The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease.
Topics: Adult; Chronic Disease; Female; Gastric Acid; Humans; Liver Diseases; Male; Middle Aged; Omeprazole | 1988 |